Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
2005 · New England Journal of Medicine · 5,074 citations
https://doi.org/10.1056/nejmoa052306
J
José Baselga
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.4K
Papers
117.7K
Citations
143
h-index
415
i10-index
José Baselga is an academic researcher from Hebron University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & PI3K/AKT/mTOR signaling in cancer & Advanced Breast Cancer Therapies. The author has an h-index of 143, co-authored 1173 publications.
ORCID: 0000-0003-1361-4063Papers by this author
worksPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
2014 · The Lancet · 4,585 citations
https://doi.org/10.1016/s0140-6736(13)62422-8
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
2019 · Nature Genetics · 4,300 citations
https://doi.org/10.1038/s41588-018-0312-8
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
2017 · Nature Medicine · 3,415 citations
https://doi.org/10.1038/nm.4333
A view on drug resistance in cancer
2019 · Nature · 2,622 citations
https://doi.org/10.1038/s41586-019-1730-1
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 · Science · 2,403 citations
https://doi.org/10.1126/science.1228522
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat